Does Medical Aid Cover GLP-1 Weight Loss Injections in South Africa?
Share
A clear, honest guide to what Ozempic, Wegovy and Mounjaro cost in 2026 — and what your scheme will and won't pay for.
If you've been researching GLP-1 medications like Ozempic, Wegovy or Mounjaro, cost is probably one of the first things you searched. You're not alone. It's the question we hear most often, and it deserves a straight answer.
The short version: for most South Africans using a GLP-1 for weight loss, medical aid will not cover it. But the picture is more nuanced than that, and understanding it properly could save you money — or prevent you from making decisions based on incomplete information.
What GLP-1 medications are currently available in South Africa?
Before getting into cost and cover, it helps to know what you're actually choosing between. The main options available in South Africa as of 2026 are:
Ozempic (semaglutide) — Registered by SAHPRA for type 2 diabetes. Widely used off-label for weight management. A once-weekly injection available in 0.25 mg, 0.5 mg and 1 mg doses.
Wegovy (semaglutide) — The higher-dose version of semaglutide, registered specifically for weight management. Launched in South Africa in August 2025. Doses go up to 2.4 mg weekly.
Mounjaro (tirzepatide) — A dual GLP-1/GIP receptor agonist, initially registered for type 2 diabetes in December 2024 and approved for weight management by SAHPRA in October 2025. Marketed in South Africa by Aspen Pharmacare.
Saxenda (liraglutide) — A daily injection registered for weight management. Older and generally less effective than the options above, but has been available longer and may have more scheme coverage precedent.
All of these are prescription-only medications. None can be purchased legally without a valid script from a registered medical practitioner.
What do GLP-1 medications cost in South Africa in 2026?
Prices vary by medication, dose and dispensing pharmacy. Here is a realistic picture based on current Medicine Price Registry data and dispensing trends:
| Medication | Approximate monthly cost |
|---|---|
| Ozempic 0.5 mg weekly | R1,400 – R1,800 |
| Ozempic 1 mg weekly | R2,000 – R2,900 |
| Wegovy (maintenance dose 2.4 mg) | R3,500 – R5,500 |
| Mounjaro (varies by dose, 2.5–15 mg) | R3,500 – R6,000+ |
| Saxenda (daily liraglutide) | R1,200 – R2,500 |
These are out-of-pocket cash-pay estimates. Prices at Clicks, Dis-Chem and Medirite are broadly similar at the same dose. The dose you need is determined by your clinical response — most patients titrate upward over the first several months, meaning costs increase as treatment progresses.
Important: significantly cheaper versions being sold online, through social media or by unregistered providers are not legitimate branded products. SAHPRA has issued multiple warnings about counterfeit and compounded GLP-1 products circulating in South Africa. These have not been evaluated for safety, quality or efficacy, and in some cases have caused patient harm.
Why doesn't medical aid cover GLP-1s for weight loss?
The answer lies in how South Africa's medical aid system is structured.
Medical schemes are legally required to cover a defined set of Prescribed Minimum Benefits (PMBs) — conditions and treatments that must be funded regardless of plan type. Type 2 diabetes is a PMB condition. Obesity is not.
This single distinction has enormous downstream consequences. Because obesity has not been classified as a Prescribed Minimum Benefit by the Council for Medical Schemes, schemes have no legal obligation to fund its treatment — including GLP-1 medications prescribed for weight management.
Until that changes at a regulatory level, most schemes will continue to treat weight loss as a lifestyle matter rather than a medical one. Advocacy work by bodies like the South African Metabolic Medicine and Surgery Society (SAMMSS), which published updated obesity treatment guidelines in November 2025, is putting pressure on this position — but the funding landscape has not yet shifted.
When will medical aid cover a GLP-1?
There is one situation where cover is genuinely possible: if you have a confirmed diagnosis of type 2 diabetes.
GLP-1 medications registered for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Soliqua) are on the formularies of most major medical schemes. Cover under the Chronic Illness Benefit or Chronic Disease Benefit is possible, but only if:
- You have a confirmed type 2 diabetes diagnosis on your scheme's system
- Your treating doctor submits a clinical motivation with supporting pathology
- The medication appears on your scheme's formulary
- Your specific plan option includes chronic medication cover at the relevant tier
What the major schemes say
Discovery Health: Covers GLP-1 agonists for members registered for type 2 diabetes on the Chronic Illness Benefit, where the scheme's clinical criteria are met. If criteria are not met, the cost falls to day-to-day benefits (Medical Savings Account or Above Threshold Benefit). Does not cover GLP-1s for weight management in non-diabetic members. Saxenda (liraglutide) for obesity is funded from day-to-day benefits only, subject to plan type.
Momentum Health: Similar to Discovery — chronic cover possible for type 2 diabetes where criteria and formulary requirements are met. Weight management cover is not available as a chronic benefit.
Bonitas: Covers 45 chronic conditions including type 2 diabetes under its Chronic Disease Benefit, subject to formulary and network pharmacy requirements. GLP-1s for weight loss are not included.
The position across schemes is consistent: diabetes diagnosis opens a potential pathway; weight management alone does not.
How to check whether you might qualify for scheme cover
If you have type 2 diabetes and are considering a GLP-1, here are the steps worth taking before assuming you'll pay out of pocket:
- Contact your scheme's clinical team — not the general helpline — and ask specifically whether semaglutide or tirzepatide is covered under your plan for type 2 diabetes management
- Check your scheme's formulary by searching for "semaglutide" or "tirzepatide" in your member portal
- Ask your doctor to submit a clinical motivation that includes your HbA1c, current treatment history and cardiovascular risk profile
- Request any refusal in writing and ask whether an appeal process exists
- Check annually — benefit structures change at renewal and the landscape for GLP-1 coverage is evolving
If you're paying out of pocket, how can you manage the cost?
Most patients using GLP-1s for weight management in South Africa currently self-fund. Here is how to do that as efficiently as possible:
Use a cash-price pharmacy. Clicks, Dis-Chem and Medirite all stock branded medications and their prices are governed by the Medicines Price Registry. Compare before you commit.
Start at the lowest effective dose. Titrating slowly is medically recommended anyway — it reduces gastrointestinal side effects and means lower costs in the early months of treatment.
Commit to a supervised programme. Patients who combine GLP-1 therapy with medical oversight, dietary support and exercise achieve better outcomes at every dose. Getting the most from the medication at the lowest possible dose is the most cost-effective approach.
Do not source medication from unregistered suppliers. The cost savings are not real. Counterfeit and substandard products have been documented in South Africa. Your safety is not worth the risk.
What is the outlook for coverage?
The pressure on schemes to fund obesity treatment is growing, and several developments are worth watching:
- The World Health Organisation is reviewing whether to add GLP-1s to its Essential Medicines List — a move that typically influences national policy
- SAMMSS published updated clinical guidelines in November 2025 explicitly recommending GLP-1 use for obesity treatment
- The patent on semaglutide expires in several markets in 2026, which is expected to drive down prices significantly when generics become available
- Discovery's own modelling suggests prices would need to fall below R1,000 per month for widespread medical aid coverage to become economically viable
The direction is clear. But the timelines are uncertain, and the current reality is that for most South Africans, GLP-1 therapy for weight management is an out-of-pocket expense.
The bottom line
| Situation | Likely outcome |
|---|---|
| Type 2 diabetes, criteria met, correct plan | Cover under Chronic Illness Benefit possible |
| Type 2 diabetes, criteria not met | May draw from day-to-day benefits (MSA) |
| Weight management only, no diabetes diagnosis | No scheme cover — out of pocket |
| Saxenda for obesity (any scheme) | Day-to-day benefits only, subject to plan |
GLP-1 medications are clinically meaningful treatments, not lifestyle products. The evidence from the STEP and SURMOUNT trials is robust, and the global medical community increasingly treats obesity as a chronic, biological disease. South Africa's funding framework has not yet caught up with that science.
In the meantime, the most important thing you can do is work with a registered, experienced prescriber who understands dosing, monitoring and the full clinical picture — not just the prescription.
This article is for educational purposes and reflects the funding landscape as of 2026. Medical aid benefits change annually. Always confirm cover directly with your scheme.
Rho is a medically supervised GLP-1 weight management clinic operating across South Africa. All consultations are conducted by registered medical doctors.